News

Jim Cramer On Bristol-Myers Squibb: “Waiting For It To Bottom”
Among the safety stocks discussed by Cramer during the episode on May 14, Bristol-Myers Squibb Company (NYSE:BMY) was first ...
Options Corner: Political Turmoil Sets Up A Contrarian Call Spread For Bristol-Myers Squibb
Although the Trump administration's healthcare policies pose risks for Bristol-Myers Squibb, the chaos opens a contrarian door for BMY stock.
Bristol-Myers Curbs Investor $6.4 Billion Payout Suit on Appeal
Bristol-Myers Squibb Co. prevailed against investor allegations it misled them about a payout tied to Food and Drug ...
TCTMD17h
Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding
In patients with venous thromboembolism (VTE) who are candidates for oral anticoagulation, apixaban results in fewer ...
Replimune Group: Analysts Are More Optimistic Than The Market
Replimune Group shares fell 28% on heavy volume with no news, despite a promising July 2025 PDUFA date for RP1 in advanced ...
University of Bristol13h
Research Excellence Framework
57% of the University's research achieved the top 'world-leading' 4* rating, compared to a sector average of 41%. 37% of Bristol's research was judged to be 'internationally excellent' and received ...